Prometheus Biosciences Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following report that they exploit animals for product testing.
Our PR600 program targets a member of the TNF super family, whose expression is limited to immune cells. It has been shown that blocking this target inhibits disease in multiple third-party IBD animal models. (Page 3) Read the full document
Prometheus Biosciences, Inc., incorporated on October 26, 2016, is a biotechnology company. The Company is engaged in the discovery, development, and commercialization of therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD). Its precision medicine platform Prometheus360, which includes gastrointestinal (GI) bioinformatics databases, to identify therapeutic targets and develop therapeutic candidates to engage the targets.
Company Website: https://www.prometheusbiosciences.com